A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1010 in Healthy Adults
NCT05606965
Recruiting
The main purpose of the study is to evaluate the safety, reactogenicity, and the humoral immunogenicity of mRNA-1010 and comparator influenza vaccines against homologous influenza A and B strains at Day 29.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
03/09/2025
Locations: Washington University in St. Louis, Saint Louis, Missouri
Conditions: Influenza
Register for Updates
The HPV 9-10 Trial: Early Initiation of HPV Vaccination
NCT04722822
Recruiting
Every year, thousands of Americans die from cancers related to human papillomavirus (HPV). The vast majority of those deaths could be prevented with a safe and effective vaccine, yet many parents choose not have their children vaccinated when it is recommended at age 11 or 12. In this study, we will examine in a randomized trial whether earlier initiation of the vaccine at age 9-10 years will result in less parental refusal and higher rates of full vaccination at younger ages, before early sexua... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/07/2025
Locations: University of California at Los Angeles, Los Angeles, California +1 locations
Conditions: HPV
Register for Updates
Impact of Reactogenicity of the 2024-2025 COVID-19 Vaccines on Health Care Workers and First Responders in the United States
NCT06633835
Active Not Recruiting
To assess the impact of reactogenicity among health care workers and first responders receiving an updated 2024-25 Novavax COVID-19 vaccine as compared with those receiving an updated 2024-25 Pfizer-BioNTech mRNA COVID-19 vaccine
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/07/2025
Locations: University of Utah School of Medicine, Salt Lake City, Utah
Conditions: COVID-19, Vaccine-Preventable Diseases, SARS CoV 2 Infection
Register for Updates
Allogeneic CMV-Specific CD19-CAR T Cells Plus CMV-MVA Triplex Vaccine After Matched Related Donor Hematopoietic Cell Transplant for the Treatment of Patients With High-Risk Acute Lymphoblastic Leukemia
NCT06735690
Recruiting
This early phase I trial tests the safety and side effects of allogeneic CMV-specific CD19-CAR T cells plus CMV-MVA vaccine and how well it works in treating patients with high-risk acute lymphoblastic leukemia after a matched related donor (allogeneic) hematopoietic stem cell transplant (alloHSCT). Chimeric antigen receptor (CAR) T-cell therapy is a type of treatment in which T cells (a type of immune system cell) are changed in the laboratory so they will attack cancer cells. T cells are taken... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/07/2025
Locations: City of Hope Medical Center, Duarte, California
Conditions: Acute Lymphoblastic Leukemia
Register for Updates
A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine When Given to Healthy Children 12 to 15 Months of Age
NCT06740630
Recruiting
The purpose of this study is to assess the consistency of immune response to three different lots of GSK's investigational varicella vaccine (VNS Vaccine), and to compare the safety and immune response of VNS vaccine to an already approved varicella vaccine (VV) known as Varivax. The study will be conducted in healthy children aged 12 to 15 months, who have neither contracted varicella nor received a varicella vaccination.
Gender:
ALL
Ages:
Between 12 months and 15 months
Trial Updated:
03/06/2025
Locations: GSK Investigational Site, Tampa, Florida +4 locations
Conditions: Chickenpox
Register for Updates
CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant
NCT06059391
Recruiting
This phase II clinical trial tests how well the cytomegalovirus-modified vaccinica Ankara (CMV-MVA) Triplex vaccine given to human leukocyte antigens (HLA) matched related stem cell donors works to prevent cytomegalovirus (CMV) infection in patients undergoing hematopoietic stem cell transplant. The CMV-MVA Triplex vaccine works by causing an immune response in the donors body to the CMV virus, creating immunity to it. The donor then passes that immunity on to the patient upon receiving the stem... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
03/06/2025
Locations: City of Hope Medical Center, Duarte, California +2 locations
Conditions: Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, BCR-ABL1 Positive, Hematopoietic and Lymphoid System Neoplasm, Hodgkin Lymphoma, Myelodysplastic Syndrome, Myelofibrosis, Myeloproliferative Neoplasm, Non-Hodgkin Lymphoma
Register for Updates
Salmonella Conjugates CVD 1000: Study of Responses to Vaccination With Trivalent Invasive Salmonella Disease Vaccine
NCT03981952
Completed
This is a randomized, placebo-controlled dose-escalation study. The main purpose of this research is to test the safety and measure the immune response of the trivalent vaccine against invasive Salmonella disease. The vaccine will be tested over a range of doses.
Gender:
ALL
Ages:
Between 18 years and 45 years
Trial Updated:
03/06/2025
Locations: University of Maryland, Baltimore, Center for Vaccine Development and Global Health, Baltimore, Maryland
Conditions: Risk Reduction
Register for Updates
Blood Donor CVD 5000
NCT03971669
Recruiting
This is an open-label, non-randomized study. Volunteers will be vaccinated with the typhoid oral vaccine, Vivotif. Vivotif has been licensed by the Food and Drug Administration (FDA) for travelers to developing countries. Volunteers will also be asked to provide blood, saliva, and stool specimens over a follow-up time period of up to eight years. The specimens obtained in this clinical research study will be used to further the investigator's understanding of the protective immunological mechani... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/05/2025
Locations: University of Maryland, Baltimore, Center for Vaccine Development and Global Health, Baltimore, Maryland
Conditions: Risk Reduction
Register for Updates
Folate Receptor Alpha Dendritic Cells (FRαDCs) or Placebo for the Treatment of Patients with Stage III or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, FAROUT Trial
NCT06639074
Recruiting
This phase II trial compares the effect of folate receptor alpha dendritic cells (FRαDCs) to placebo in treating patients with stage III or IV ovarian, fallopian tube or primary peritoneal cancer. FRαDCs, a dendritic cell vaccine, is made from a person's white blood cells. The white blood cells are treated in the laboratory to make dendritic cells (a type of immune cell) mixed with folate receptor alpha (FRalpha), a protein found in high levels on ovarian tumor cells. FRαDCs work by boosting the... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
03/04/2025
Locations: Mayo Clinic in Arizona, Scottsdale, Arizona +2 locations
Conditions: Advanced Fallopian Tube Carcinoma, Advanced Fallopian Tube High Grade Serous Adenocarcinoma, Advanced Ovarian Carcinoma, Advanced Ovarian Carcinosarcoma, Advanced Ovarian Clear Cell Adenocarcinoma, Advanced Ovarian Endometrioid Adenocarcinoma, Advanced Ovarian High Grade Serous Adenocarcinoma, Advanced Primary Peritoneal Carcinoma, Advanced Primary Peritoneal High Grade Serous Adenocarcinoma, Fallopian Tube Carcinosarcoma, Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, FIGO Stage III Ovarian Cancer 2014, FIGO Stage IV Ovarian Cancer 2014, Ovarian Mixed Cell Adenocarcinoma, Primary Peritoneal Carcinosarcoma, Primary Peritoneal Clear Cell Adenocarcinoma, Primary Peritoneal Endometrioid Adenocarcinoma
Register for Updates
CIMAvax Vaccine, Nivolumab, and Pembrolizumab in Treating Patients With Advanced Non-small Cell Lung Cancer or Squamous Head and Neck Cancer
NCT02955290
Suspended
This phase I/II trial studies the best dose and side effects of recombinant human EGF-rP64K/montanide ISA 51 vaccine (CIMAvax) and nivolumab and to see how well they work in treating patients with non-small cell lung cancer or squamous head and neck cancer that has spread to other places in the body. Vaccine therapy, such as CIMAvax vaccine may help slow down and stop tumor growth. Immunotherapy with monoclonal antibodies, such as nivolumab and pembrolizumab, may help the body's immune system at... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/26/2025
Locations: Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, Indiana +4 locations
Conditions: Advanced Head and Neck Squamous Cell Carcinoma, Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, PD-L1 Positive, Recurrent Head and Neck Squamous Cell Carcinoma, Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8, Unresectable Lung Non-Small Cell Carcinoma, Advanced Squamous Non-Small Cell Lung Carcinoma
Register for Updates
Influenza Vaccination for Flu Prevention in Patients With Plasma Cell Disorders
NCT04080531
Completed
This phase IV trial studies how well influenza vaccination works in preventing infections such as influenza in patients with plasma cell disorders. Influenza infections may theoretically support the growth of tumor cells and improving protection against influenza may improve the status of patients' plasma cell disorder. Giving influenza vaccination may reduce influenza-related complications including infections, hospitalizations, and deaths, and improve the status of plasma cell disorders.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/24/2025
Locations: Emory University Hospital Midtown, Atlanta, Georgia +1 locations
Conditions: Plasma Cell Neoplasm
Register for Updates
The Efficacy of the 2023-2024 Updated COVID-19 Vaccines Against COVID-19 Infection
NCT06065176
Completed
The purpose of this research study is to find out how well two different 2023-2024 updated COVID-19 vaccines protect people from COVID-19 (the disease caused by the SARS-CoV-2 virus), and to determine if getting a 2023-2024 updated vaccine provides better protection from COVID-19 than not getting a vaccine. If the participant chooses to get a 2023-2024 updated COVID-19 vaccine as part of this study, they will have a 50/50 chance of receiving either the Novavax or Pfizer mRNA vaccine. If the pa... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/21/2025
Locations: University of Utah School of Medicine, Salt Lake City, Utah
Conditions: COVID-19, Vaccine-Preventable Diseases, SARS CoV 2 Infection, Upper Respiratory Tract Infection, Upper Respiratory Disease
Register for Updates